Micro RNA-155 inhibitor as a potential therapeutic strategy for the treatment of acute kidney injury (AKI): a nanomedicine perspective. Issue 29 (30th April 2018)

• Record Type: Journal Article
• Authors: Chen, Shunjie; Shan, Jianping; Niu, Wei; Lin, Fujun; Liu, Shuang; Wu, Ping; Sun, Lijing; Lu, Wei; Jiang, Gengru
• Is Part Of: RSC advances. Volume 8:Issue 29(2018)
• Page Start: 15890
• Page End: 15896
• Publication Date: 2018-04-30
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c7ra13440a
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : In this study, we have prepared miR-155 inhibitor-loaded liposome vesicles for the effective treatment of acute kidney injury. Abstract : In this study, we have prepared miR-155 inhibitor-loaded liposome vesicles for the effective treatment of acute kidney injury. The efficacy of liposomal miR-155 inhibitor in the expression of miR-155, mortality in animals, the expression of TNF-α-IL6, and the expression of SOCS1–STAT1 were evaluated. The loading of miR-155 inhibitor into liposomes conferred the much needed colloidal stability and efficient delivery to the renal tissues. The study clearly shows that miR-I-LV significantly decreases the expression of miR-155 in kidneys compared to LPS. Administration of miR-I-LV remarkably reduced the pathological concerns of the kidneys with a marked decrease in inflammatory cell infiltration. Scrambled miR-155 did not have any effect on the expression of these markers; however miR-I-LV showed a remarkable ability to decrease the expression of TNF-α and IL-6 in kidney tissues indicating an ability to treat acute kidney infections. Overall, administration of miR-155 inhibitor effectively alleviated LPS-induced kidney injury by significantly suppressing TNF-α and IL-6 in kidney tissue and by remarkably increasing the expression of mRNA of SOCS1 and STAT1. The present results suggest that miR-155 inhibitor could be used in an effective targeting strategy for the treatment of acute kidney injury (AKI).